Valeant Said to Keep Salix After Takeda Deal Falls Apart
Valeant Pharmaceuticals International Inc. has decided to keep and invest in its gastrointestinal-drugs division after talks to sell the unit to Takeda Pharmaceutical Co. fell apart, according to people familiar with the matter.
from Biotech News
0 Comments